Weight Loss Plateaus Are Normal and Seen in Every Major GLP-1/GIP Study The Standard Weight-Loss Curve Clinical trials consistently show that weight loss with GLP-1 and GLP-1/GIP medications follows a predictable pattern: Rapid weight loss early Gradual slowing over time A plateau phase where weight stabilizes This pattern has been observed across: Semaglutide trials ( STEP program ) Tirzepatide trials ( SURMOUNT-1 , SURMOUNT-4 ) Long-term cardiovascular outcomes studies ( SELECT ) In these studies, most participants lost weight more rapidly during the first several months, then experienced a gradual slowing and reached their average maximum weight loss around 918 months , after which weight tended to stabilize rather than continue to drop indefinitely
Moderate weight loss was found to be a common side effect of the drug, and the FDA approved a different formulation of semaglutide, called Wegovy, for that purpose in 2021
Lifestyle Adjustments for Success Lifestyle adjustments, including dietary changes and increased physical activity, are crucial for successful weight loss with semaglutide
Nausea/vomiting and belching Nausea and vomiting are common side effects of semaglutide
The Truth About Ozempic for PCOS Weight Loss